Cephalosporin Drugs Market Analysis| Coherent Market Insights

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. CEPHALOSPORIN DRUGS MARKET ANALYSIS Cephalosporin Drugs Market,ByGeneration (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2019 – 2026.

3. The global cephalosporin drugs market size was valued at US$ 14,240.0 million in 2018, and is expected to witness a CAGR of 3.8% over the forecast period (2019 – 2026). Growth Drivers • Approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

4. Increasing research and development activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period.

5. Global Cephalosporin Drugs Market Share (%) Analysis, By Generation, 2018 & 2026

6. Market Restraints Increasing cephalosporin drug recalls by regulatory bodies is hampering the cephalosporin drugs market growth. For instance, in August 2014, Caraco Pharmaceutical Laboratories Ltd., a unit of Sun Pharmaceutical Industries Ltd., initiated a recall of multiple lots of Cephalexin capsules from the U.S. market. According to a notification by the U.S. FDA, the recall of 340,553 units of 500 mg and 113,677 units of 250 mg bottles was voluntarily initiated by the company through a letter to the regulator in June 2014 under ‘Class-II’ classification, owing to Current Good Manufacturing Practice (CGMP) deviations.

7. Regional Insights • On the basis of region, the global cephalosporin drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global cephalosporin drugs market during the forecast period, owing to increasing number of product launches. For instance, in August 2017, Dr. Reddy’s Laboratories Ltd. launched Cefixime for Oral Suspension, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, in the U.S. market. The Suprax brand and generic had US sales of approximately US$ 50.5 million for the 12 months ended in June 2017.

8. Asia Pacific is expected to foresee a rapid growth in the cephalosporin drugs market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to increasing strategic partnership for distribution of cephalosporin drugs. For instance, in September 2017, BasileaPharmaceutica Ltd. announced that its subsidiary, BasileaPharmaceutica International Ltd. (Basilea), entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for Basilea's antibiotic Zevtera (ceftobiprole) in China.

9. Global Cephalosporin Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026

10. Competitive Section Key players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, BasileaPharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG.

11. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/cephalosporin-drugs-market-2893

12. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

13. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/